Genetics, Subtypes, and Beyond the Adrenals

While all children with Familial Glucocorticoid Deficiency (FGD) share the core challenge of low cortisol, the underlying “instruction manual”—their genetics—can vary significantly. Knowing your child’s specific genetic subtype is like having a more detailed map of their health; it helps your medical team know which other systems in the body might need a little extra attention ^[1][2].

The Genetic Landscape

FGD is an autosomal recessive condition. This means a child must usually inherit two changed (mutated) copies of a gene—one from each parent—to have the condition ^[3]. If both parents are confirmed carriers, each pregnancy has a 25% chance of being affected.

Researchers have identified several different genes that can cause FGD, which are often grouped into “classic” and “non-classic” types:

• Classic FGD (Types 1 and 2): These are the most common forms.

  • MC2R (Type 1): Accounts for about 25% of cases ^[1].
  • MRAP (Type 2): Accounts for about 15–20% of cases ^[1].
    In these types, the problem is almost always limited to the adrenal glands and cortisol production ^[4].

• Non-Classic and Syndromic FGD: These involve genes that play roles in other parts of the body beyond just the adrenal glands.

  • NNT: This gene helps protect cells from “oxidative stress.” While it primarily causes cortisol deficiency, some children may also develop issues with their thyroid, heart, or reproductive system (gonads) over time, and some develop mineralocorticoid deficiency ^[5][6].
  • STAR: Some children have “partial” defects in this gene. While severe defects cause a different condition called Lipoid CAH, partial defects can look exactly like FGD but may occasionally involve salt-balancing issues or reproductive health questions later in life ^[7][8].
  • SGPL1: This is a more complex “syndromic” form. In addition to adrenal issues, it is frequently linked to nephrotic syndrome (a serious kidney condition), low white blood cell counts, and skin changes like ichthyosis ^[9][10].
  • MCM4 and TXNRD2: These are very rare causes that may involve the immune system or heart/electrocardiographic changes, respectively ^[11][12].

Important: These gene-specific associations are highly variable. They do not mean every child will develop these issues, but they do guide your endocrinologist and geneticist in creating a personalized screening plan.

Why Genotype Isn’t a Perfect Crystal Ball

One of the most surprising things about FGD is its variability. Even within the same family, two siblings with the exact same genetic mutation (genotype) may have different symptoms or a different age when the condition first appears (phenotype) ^[13].

One child might be diagnosed as a newborn because of dark skin (hyperpigmentation) or low blood sugar, while another child with the same gene might not show signs until they are a toddler ^[3][14]. This is why doctors treat the child, not just the genetic report, and adjust care based on how your child is growing and feeling ^[15].

Navigating Genetic Testing

If your child is suspected of having FGD, your doctor will likely recommend genetic testing. This is typically done through a blood or saliva sample.

1. Targeted Panels: Often, doctors start with a “panel” that looks at the most common genes (MC2R, MRAP, STAR, NNT). This is efficient and finds the answer for about half of all patients ^[1].
2. Whole-Exome or Whole-Genome Sequencing: If the initial panel is negative, your doctor may recommend broader testing. Whole-Exome Sequencing (WES) looks at the protein-coding parts of genes but may miss certain regulatory variants. Whole-Genome Sequencing (WGS) covers a broader portion of the DNA and can find diagnoses missed by WES ^[16][2].

Roughly 40% of children with FGD symptoms do not yet have a known genetic cause ^[1]. If your child’s tests are negative, it doesn’t mean they don’t have FGD; it just means science hasn’t identified their specific “spelling error” yet. In these cases, your team will continue to manage the symptoms based on established clinical guidelines ^[17].